Husgafvel-Pursiainen K - Search Results

1

N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.

Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. Bouchardy C, et al. Pharmacogenetics. 1998 Aug;8(4):291-8. doi: 10.1097/00008571-199808000-00002. Pharmacogenetics. 1998. PMID: 9731715

2

Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on lung cancer risk in smokers.

Jourenkova N, Reinikanen M, Bouchardy C, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. Jourenkova N, et al. Pharmacogenetics. 1997 Dec;7(6):515-8. doi: 10.1097/00008571-199712000-00010. Pharmacogenetics. 1997. PMID: 9429237 No abstract available.

3

Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.

Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H. Hirvonen A, et al. Pharmacogenetics. 1992 Dec;2(6):259-63. doi: 10.1097/00008571-199212000-00003. Pharmacogenetics. 1992. PMID: 1306126

4

PCR-based CYP2D6 genotyping for Finnish lung cancer patients.

Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. Hirvonen A, et al. Pharmacogenetics. 1993 Feb;3(1):19-27. doi: 10.1097/00008571-199302000-00002. Pharmacogenetics. 1993. PMID: 8097947

5

Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals.

Saarikoski ST, Reinikainen M, Anttila S, Karjalainen A, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. Saarikoski ST, et al. Pharmacogenetics. 2000 Mar;10(2):183-5. doi: 10.1097/00008571-200003000-00010. Pharmacogenetics. 2000. PMID: 10762006 No abstract available.

6

CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships.

Laforest L, Wikman H, Benhamou S, Saarikoski ST, Bouchardy C, Hirvonen A, Dayer P, Husgafvel-Pursiainen K. Laforest L, et al. Eur J Cancer. 2000 Sep;36(14):1825-32. doi: 10.1016/s0959-8049(00)00185-4. Eur J Cancer. 2000. PMID: 10974631

7

Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk.

Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stücker I, To-Figueras J, Brennan P, Taioli E. Benhamou S, et al. Carcinogenesis. 2002 Aug;23(8):1343-50. doi: 10.1093/carcin/23.8.1343. Carcinogenesis. 2002. PMID: 12151353

8

Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.

Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K, Vainio H. Hirvonen A, et al. J Natl Cancer Inst. 1996 Dec 18;88(24):1853-6. doi: 10.1093/jnci/88.24.1853. J Natl Cancer Inst. 1996. PMID: 8961976

9

CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.

Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Rautalahti M, Haukka J, Impivaara O, Järvisalo J, Vainio H, Hirvonen A. Saarikoski ST, et al. Pharmacogenetics. 2000 Feb;10(1):5-10. doi: 10.1097/00008571-200002000-00002. Pharmacogenetics. 2000. PMID: 10739167 Clinical Trial.

10

CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population.

Bouchardy C, Wikman H, Benhamou S, Hirvonen A, Dayer P, Husgafvel-Pursiainen K. Bouchardy C, et al. Biomarkers. 1997;2(2):131-4. doi: 10.1080/135475097231869. Biomarkers. 1997. PMID: 23889070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters